Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aradigm/Novo Nordisk Inhaled Insulin Manufacturing Issues Appear Resolved

This article was originally published in The Pink Sheet Daily

Executive Summary

Concerns over cosmetic blemishes on liquid insulin strips had delayed initiation of additional Phase III trials. Aradigm sees increased interest in its AERx pulmonary delivery system in the wake of Pfizer’s recent optimism about Exubera.

You may also be interested in...



Oralin Buccal Insulin May Face Easier Regulatory Path Than Inhaled Insulins, Generex Consultant Predicts

Oralin exposes only the oral cavity to insulin, Generex consultant Fleming says. Generex will pursue international approvals first with a more limited data package than FDA requires. Phase IIb trials have started in type 2 diabetes.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Neurology At The Forefront Of US FDA Complex Innovative Trial Design Pilot

Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.

Topics

UsernamePublicRestriction

Register

PS058585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel